Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

Clinical Trial ID NCT02077114

PubWeight™ 9.03‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02077114

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology 2015 1.13
2 Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res 2015 1.09
3 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
4 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
5 Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014 1.01
6 Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. Front Oncol 2014 0.85
7 Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016 0.81
8 Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology 2015 0.78
9 The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget 2016 0.76
10 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
Next 100